About: ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer
Creator	Blackhall, Fiona Addeo, Alfredo Peters, Solange Reck, Martin Dziadziuszko, Rafal Bouchaab, Hasna De Marinis, Filippo Felip, Enriqueta Garnier, Christophe Passaro, Antonio Planchard, David
source	Medline; PMC
abstract	The COVID-19 pandemic, characterised by a fast and global spread during the first months of 2020, has prompted the development of a structured set of recommendations for cancer care management, to maintain the highest possible standards. Within this framework, it is crucial to ensure no disruption to essential oncological services and guarantee the optimal care. This is a structured proposal for the management of lung cancer, comprising three levels of priorities, namely: tier 1 (high priority), tier 2 (medium priority) and tier 3 (low priority)—defined according to the criteria of the Cancer Care Ontario, Huntsman Cancer Institute and Magnitude of Clinical Benefit Scale. The manuscript emphasises the impact of the COVID-19 pandemic on lung cancer care and reconsiders all steps from diagnosis, staging and treatment. These recommendations should, therefore, serve as guidance for prioritising the different aspects of cancer care to mitigate the possible negative impact of the COVID-19 pandemic on the management of our patients. As the situation is rapidly evolving, practical actions are required to guarantee the best patients’ treatment while protecting and respecting their rights, safety and well-being. In this environment, cancer practitioners have great responsibilities: provide timely, appropriate, compassionate and justified cancer care, while protecting themselves and their patients from being infected with COVID-19. In case of shortages, resources must be distributed fairly. Consequently, the following recommendations can be applied with significant nuances, depending on the time and location for their use, considering variable constraints imposed to the health systems. An exceptional flexibility is required from cancer caregivers.
has issue date	2020-06-23(xsd:dateTime)
bibo:doi	10.1136/esmoopen-2020-000820
bibo:pmid	32581069
has license	cc-by-nc
sha1sum (hex)	c09d81f3b94e4c1a03d169fd71361fe05d2b7dcf
schema:url	https://doi.org/10.1136/esmoopen-2020-000820
resource representing a document's title	ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer
has PubMed Central identifier	PMC7319703
has PubMed identifier	32581069
schema:publication	ESMO Open
resource representing a document's body	covid:c09d81f3b94e4c1a03d169fd71361fe05d2b7dcf#body_text
is schema:about of	named entity 'Lung cancer' named entity 'COVID-19' named entity 'nivolumab' named entity 'COVID' named entity 'paraneoplastic syndromes' named entity 'SARS-CoV-2' named entity 'NHS' named entity 'pros and cons' named entity 'lung cancer' named entity 'Cancer Care Ontario' named entity 'Telemedicine' named entity 'tumour' named entity 'England' named entity 'spinal cord compression' named entity 'SCLC' named entity 'NON-SMALL CELL LUNG CANCER' named entity 'tumour' named entity 'lung cancer' named entity 'immunotherapy' named entity 'lung cancer' named entity 'lung malignancy' named entity 'radiation therapy' named entity 'lung cancer' named entity 'cancer treatments' named entity 'quality of life' named entity 'PCI' named entity 'NHS' named entity 'health systems' named entity 'telemedicine' named entity 'NSCLC' named entity 'radiotherapy' named entity 'morbidity' named entity 'chemotherapy' named entity 'EARLY STAGE' named entity 'adjuvant chemotherapy' named entity 'therapeutic strategies' named entity 'lung cancer' named entity 'metastatic' named entity 'COVID-19 outbreak' named entity 'haemoptysis' named entity 'psychosocial' named entity 'Centers for Disease Control and Prevention' named entity 'mg 30' named entity 'stage II' named entity 'chemotherapy' named entity 'chemotherapy' named entity 'intensive care unit' named entity 'metastatic' named entity 'lung cancer' named entity 'granulocyte' named entity 'healthcare professionals' named entity 'COVID-19' named entity 'personal protective equipment' named entity 'NON-SMALL CELL LUNG CANCER' named entity 'palliative' named entity 'clinical guide' named entity 'tumour' named entity 'outpatient' named entity 'SARS-CoV-2' named entity 'public health' named entity 'COVID-19 pandemic' named entity 'infection' named entity 'COVID' named entity 'tumours' named entity 'prognosis' named entity 'radiotherapy' named entity 'pharmacological' named entity 'curative intent' named entity 'post-operative' named entity 'clinical trial' named entity 'lung cancer'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software